BiotechTube

ASP8374 + cemiplimab

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma

Conditions

Glioblastoma, Recurrent Glioblastoma

Trial Timeline

Mar 9, 2022 → Jan 1, 2024

NCT ID
NCT04826393

About ASP8374 + cemiplimab

ASP8374 + cemiplimab is a phase 1 stage product being developed by Astellas Pharma for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04826393. Target conditions include Glioblastoma, Recurrent Glioblastoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04826393Phase 1Completed

Competing Products

20 competing products in Glioblastoma

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
33
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
PLX3397Daiichi SankyoPhase 2
52
Nimotuzumab + TemozolomideSun PharmaceuticalPhase 2
52
Gliadel + Avastin + TemodarEisaiPhase 2
52
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
41
KHK2455Kyowa KirinPre-clinical
23
olaratumab + ramucirumabEli LillyPhase 2
52
enzastaurin + temozolomideEli LillyPhase 1/2
41
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
52
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
52
Abemaciclib + LY3214996Eli LillyPhase 1
33
enzastaurin + lomustineEli LillyPhase 3
77
Galunisertib + Lomustine + PlaceboEli LillyPhase 2
52
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
77
DSP-7888Sumitomo PharmaPhase 1/2
41
BBI608 + TemozolomideSumitomo PharmaPhase 1/2
41
Indoximod + Temozolomide + Cyclophosphamide + Etoposide + LomustineJohnson & JohnsonPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85